ProShare Advisors
DAWN

ProShare Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

ProShare Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$713K Buy
33,247
+14,352
+76% +$202K ﹤0.01% 900
2025
Q4 		$176K Buy
18,895
+2,939
+18% +$24.6K ﹤0.01% 1758
2025
Q3 		$112K Sell
15,956
-2,589
-14% -$17.8K ﹤0.01% 1824
2025
Q2 		$121K Buy
18,545
+2,121
+13% +$14.6K ﹤0.01% 1840
2025
Q1 		$130K Sell
16,424
-2,970
-15% -$32K ﹤0.01% 1781
2024
Q4 		$246K Buy
19,394
+3,687
+23% +$51.3K ﹤0.01% 1770
2024
Q3 		$219K Buy
15,707
+1,920
+14% +$27.4K ﹤0.01% 1673
2024
Q2 		$190K Sell
13,787
-3,592
-21% -$52.6K ﹤0.01% 1542
2024
Q1 		$287K Buy
17,379
+1,447
+9% +$21.7K ﹤0.01% 1451
2023
Q4 		$233K Buy
15,932
+2,108
+15% +$25.6K ﹤0.01% 1555
2023
Q3 		$170K Buy
13,824
+2,660
+24% +$34.7K ﹤0.01% 1515
2023
Q2 		$133K Buy
+11,164
New +$146K ﹤0.01% 1643
2023
Q1 		– Sell
-9,645
Closed -$208K – 1819
2022
Q4 		$208K Buy
+9,645
New +$198K ﹤0.01% 1468
2022
Q2 		– Sell
-10,675
Closed -$106K – 1872
2022
Q1 		$106K Sell
10,675
-452
-4% -$5.97K ﹤0.01% 2016
2021
Q4 		$188K Buy
+11,127
New +$229K ﹤0.01% 2052

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

ProShare Advisors's DAWN Position: Q1 2026 in Review

ProShare Advisors increased its Day One Biopharmaceuticals (DAWN) stake by 76% in Q1 2026, buying an estimated $202K and bringing the position to 33,247 shares worth $713K. The position accounts for ﹤0.01% of the portfolio, ranked #900.

ProShare Advisors first reported a position in DAWN in Q4 2021 and has held it in 15 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • ProShare Advisors held 33,247 shares of Day One Biopharmaceuticals worth $713K as of Q1 2026.
  • ProShare Advisors bought 14,352 Day One Biopharmaceuticals shares in Q1 2026, an estimated $202K.
  • Day One Biopharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #900 holding.
  • ProShare Advisors first reported a position in Day One Biopharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.